Canakinumab Biosimilar - Research Grade

Human

IL1B

>1mg/ml

Human IgG1 Kappa

Gevokizumab Biosimilar - Research Grade (ICH5133)

https://www.imgt.org/mAb-DB/

ICH3002

P01584

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of canakinumab, a fully human anti-interleukin-1 beta (IL-1beta) monoclonal antibody, supplied for research use only. It is a human IgG1 kappa immunoglobulin built to bind human IL-1beta (UniProt P01584), the same target as the originator drug, allowing researchers to study IL-1beta neutralisation without sourcing the clinical product. It is not the clinical drug and is not intended for human or veterinary use. The material is useful as a defined, well-characterised reagent for in-vitro binding and neutralisation assays, as a positive control or benchmarking standard in cytokine-signalling and inflammasome studies, and as a tool antibody in ELISA, surface plasmon resonance, and cell-based reporter workflows. It is offered at low endotoxin (research grade below 1 EU/mg, ultra-low below 0.5 EU/mg) and in bulk milligram-to-gram quantities suitable for in-vivo standards and preclinical model work. As a functional-grade analog it supports assay development, method comparison, and mechanistic dissection of IL-1beta biology. Interleukin-1 beta (IL-1beta), encoded by IL1B, is a principal pro-inflammatory cytokine of the IL-1 family. It is produced mainly by activated monocytes and macrophages as an inactive precursor (pro-IL-1beta) that is cleaved to its mature, active form by caspase-1 following inflammasome assembly (for example the NLRP3 inflammasome). Mature IL-1beta is secreted and signals through the type 1 IL-1 receptor (IL-1R1) together with the IL-1 receptor accessory protein, driving MyD88-dependent NF-kappaB and MAPK signalling. This induces downstream mediators including IL-6, prostaglandins, and adhesion molecules, and drives fever, leukocyte recruitment, and acute-phase responses. IL-1beta activity is tightly controlled by the natural IL-1 receptor antagonist (IL-1Ra) and the decoy receptor IL-1R2. Dysregulated IL-1beta is central to autoinflammatory syndromes and many chronic inflammatory conditions, making it a validated therapeutic and research target.

IL-1 beta, Catabolin, Interleukin-1 beta, IL1F2

Detects human IL1B

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Q: Is the Canakinumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Canakinumab biosimilar suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Canakinumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Canakinumab that binds human IL1B.